These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28709160)

  • 21. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
    Kua KP; Lee SWH
    Pharmacotherapy; 2017 Jun; 37(6):755-769. PubMed ID: 28423192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Respiratory syncytial virus acute respiratory infection-associated hospitalizations in preterm Mexican infants: A cohort study.
    Benítez-Guerra D; Piña-Flores C; Zamora-López M; Escalante-Padrón F; Lima-Rogel V; González-Ortiz AM; Guevara-Tovar M; Bernal-Silva S; Benito-Cruz B; Castillo-Martínez F; Martínez-Rodríguez LE; Ramírez-Ojeda V; Tello-Martínez N; Lomelí-Valdez R; Salto-Quintana J; Cadena-Mota S; Noyola DE
    Influenza Other Respir Viruses; 2020 Mar; 14(2):182-188. PubMed ID: 31917902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan.
    Chi H; Hsu CH; Chang JH; Chiu NC; Hung HY; Kao HA; Weng LC; Huang FY; Chiu YY; Chang LY; Huang LM
    PLoS One; 2014; 9(6):e100981. PubMed ID: 24971565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro.
    Lekic E; Dragas L; Nikcevic D; Lekic J; Dedic A; Sulovic L
    Turk J Pediatr; 2024 May; 66(2):161-170. PubMed ID: 38814297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab.
    Chan P; Li A; Paes B; Abraha H; Mitchell I; Lanctôt KL;
    Pediatr Infect Dis J; 2015 Dec; 34(12):e290-7. PubMed ID: 26780032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A post-incorporation study on the use of palivizumab in the Brazilian public health system.
    Batista JDL; Ferreira MAP; Xavier CDS; Souza ITA; Cruz LN; Polanczyk CA
    Rev Inst Med Trop Sao Paulo; 2021; 63():e5. PubMed ID: 33533808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.
    Packnett ER; Winer IH; Larkin H; Oladapo A; Gonzales T; Wojdyla M; Goldstein M; Smith VC
    Hum Vaccin Immunother; 2022 Nov; 18(6):2140533. PubMed ID: 36412253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
    Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for respiratory syncytial virus bronchiolitis hospitalizations in children with chronic diseases.
    Shmueli E; Goldberg O; Mei-Zahav M; Stafler P; Bar-On O; Levine H; Steuer G; Mussaffi H; Gendler Y; Blau H; Prais D
    Pediatr Pulmonol; 2021 Jul; 56(7):2204-2211. PubMed ID: 33913611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut.
    Banerji A; Panzov V; Young M; Lee BE; Mamdani M; Giles BL; Dennis M; Morel J; Bisson D; Paes BA; Hui C; Mahony J
    Can Respir J; 2014; 21(3):185-9. PubMed ID: 24367792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
    Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
    Sanchez-Luna M; Burgos-Pol R; Oyagüez I; Figueras-Aloy J; Sánchez-Solís M; Martinón-Torres F; Carbonell-Estrany X
    BMC Infect Dis; 2017 Oct; 17(1):687. PubMed ID: 29041909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain.
    Figueras-Aloy J; Carbonell-Estrany X; Quero J;
    Pediatr Infect Dis J; 2004 Sep; 23(9):815-20. PubMed ID: 15361718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.
    Keary IP; Ravasio R; Fullarton JR; Manzoni P; Lanari M; Paes BA; Carbonell-Estrany X; Baraldi E; Tarride JÉ; Rodgers-Gray B
    PLoS One; 2023; 18(8):e0289828. PubMed ID: 37561741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation: A retrospective, observational study.
    Kamori A; Morooka Y; Yamamura K; Chong PF; Kuga N; Takahata Y; Sagawa K; Furuno K
    Medicine (Baltimore); 2021 Nov; 100(47):e27952. PubMed ID: 34964779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of immunoprophylaxis with palivizumab on respiratory syncytial virus infection in preterm infants less than 35 weeks in Colombian hospitals.
    Galvis C; Colmenares A; Cabrales L; Ibatá L; Marulanda J; Ovalle O; Puello D; Rojas C; Africano M; Ballesteros A; Posso H
    Pediatr Pulmonol; 2022 Oct; 57(10):2420-2427. PubMed ID: 35791790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of Palivizumab against Respiratory Syncytial Virus: Cohort and Case Series Analysis.
    Moore HC; de Klerk N; Richmond PC; Fathima P; Xu R; Keil AD; Snelling TL; Strunk T
    J Pediatr; 2019 Nov; 214():121-127.e1. PubMed ID: 31378522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals.
    Zylbersztejn A; Almossawi O; Gudka N; Tompsett D; De Stavola B; Standing JF; Smyth R; Hardelid P
    Br J Clin Pharmacol; 2022 Mar; 88(3):1246-1257. PubMed ID: 34478568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of the Respiratory Syncytial Virus related acute lower respiratory tract infection among hospitalized newborns: a prospective multicenter study.
    Alan S; Erdeve O; Cakir U; Akduman H; Zenciroglu A; Akcakus M; Tunc T; Gokmen Z; Ates C; Atasay B; Arsan S;
    J Matern Fetal Neonatal Med; 2016; 29(13):2186-93. PubMed ID: 26365531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.